Results 211 to 220 of about 140,304 (256)
Some of the next articles are maybe not open access.
Trends in Pharmacological Sciences, 1989
Recently the first report of zidovudine-resistant human immunodeficiency virus obtained from AIDS patients was published. Resistance to antiviral agents may result from single point mutations in the virus genome. Several mechanisms of resistance have already been elucidated at the biochemical level but the clinical significance of drug resistance is ...
H J, Field, S E, Goldthorpe
openaire +2 more sources
Recently the first report of zidovudine-resistant human immunodeficiency virus obtained from AIDS patients was published. Resistance to antiviral agents may result from single point mutations in the virus genome. Several mechanisms of resistance have already been elucidated at the biochemical level but the clinical significance of drug resistance is ...
H J, Field, S E, Goldthorpe
openaire +2 more sources
Nature Microbiology, 2019
Baloxavir marboxil (BXM) represents a promising advance in antiviral chemotherapies for influenza infections. Identification of transmissible BXM-resistant strains in Japan may hit pause on widespread adoption of this therapy and could lead to revision of surveillance practices for emerging viruses.
Karen A. Kormuth, Seema S. Lakdawala
openaire +2 more sources
Baloxavir marboxil (BXM) represents a promising advance in antiviral chemotherapies for influenza infections. Identification of transmissible BXM-resistant strains in Japan may hit pause on widespread adoption of this therapy and could lead to revision of surveillance practices for emerging viruses.
Karen A. Kormuth, Seema S. Lakdawala
openaire +2 more sources
A perspective on antiviral resistance
Journal of Clinical Virology, 2009More than 25 years after the licensure of aciclovir and then penciclovir, followed by their respective prodrugs valaciclovir and famciclovir, cases of clinically relevant resistance to these drugs in immunocompetent individuals remain very rare. The aim of this review is to focus on the mechanism of action of these anti HSV drugs and then briefly ...
openaire +2 more sources
Current Opinion in Infectious Diseases, 2014
Current genotypic resistance tests fail to amplify drug-resistant minority variants when they are present below 20% of the total virus population. Next-generation sequencing (NGS) addresses this issue and is being introduced into diagnostic laboratories. This review gives an overview of the resistance tests currently used and explores the opportunities
openaire +2 more sources
Current genotypic resistance tests fail to amplify drug-resistant minority variants when they are present below 20% of the total virus population. Next-generation sequencing (NGS) addresses this issue and is being introduced into diagnostic laboratories. This review gives an overview of the resistance tests currently used and explores the opportunities
openaire +2 more sources
New Antivirals and Antiviral Resistance
2004The field of antiviral therapy is relatively new. Whereas the first antibiotics were available in the 1940s, the first antiviral agent (idoxuridine) was not licensed until the 1960s. Furthermore, the number of antiviral agents available to clinicians today pale in comparison to the number of antibacterial agents.
openaire +2 more sources
Resistance of Viruses to Antiviral Drugs
Annual Review of Medicine, 1991In recent years, substantial advances in antiviral therapy have been made; however, in the immunocompromised host, antiviral drug resistance is becoming an issue of increasing clinical importance. Understanding the mechanism of action of antiviral agents, especially those used to treat herpesvirus infections, may enable us to design new therapeutic ...
A G, Freifeld, J M, Ostrove
openaire +2 more sources
2008
There are two classes of anti-influenza drugs - one class targets the M2 proton channel whereas the other class targets the surface glycoprotein neuraminidase.
Alan J. Hay +2 more
openaire +1 more source
There are two classes of anti-influenza drugs - one class targets the M2 proton channel whereas the other class targets the surface glycoprotein neuraminidase.
Alan J. Hay +2 more
openaire +1 more source
Cytomegalovirus (CMV) Resistance to Antivirals
American Journal of Transplantation, 2001This article reviews the biology of cytomegalovirus (CMV), the approved antiviral therapies, and mechanisms of resistance to these drugs. The rates of resistance development in clinical trials are presented, as are the assays for testing susceptibility by phenotypic and genotypic methods.
W L, Drew, C V, Paya, V, Emery
openaire +2 more sources
New Antivirals and Drug Resistance
Annual Review of Biochemistry, 2009Progress in the discovery of new antiviral medicines is tempered by the rapidity with which drug-resistant variants emerge. A review of the resistance-suppressing properties of four classes of antivirals is presented: influenza virus neuraminidase inhibitors, HIV protease inhibitors, antibodies, and protein-based fusion inhibitors.
openaire +2 more sources
Hepatitis B antivirals and resistance
Current Opinion in Virology, 2013Antiviral therapy for chronic hepatitis B (CHB) has improved the outcome of patients. However, due to the multiple selection pressures of different nucleos(t)ide analogue, drug resistant HBV variants have emerged. Because of the arrangement of overlapping reading frames in HBV genome, these variants not only have clinical implications such as drug ...
Uma, Devi, Stephen, Locarnini
openaire +2 more sources